Photostabilizing compounds are provided. In particular, the photostabilizing compounds may be heterocyclic or homocyclic. Topical compositions comprising these compounds are also provided. In particular, these topical compositions may further comprise photoactive compounds. Methods for stabilizing photoactive compounds are also provided. These methods comprise mixing the photoactive compounds with photostabilizing compounds.

A novel salt of treprostinil and methods of its preparation and use are disclosed.

The present disclosure relates to a novel compound represented by Chemical Formula 1 and an organic light emitting device using the same. The compound is used as a material of an organic material layer of the organic light emitting device. ##STR00001##

Photostabilizing compounds are provided. In particular, the photostabilizing compounds may be heterocyclic or homocyclic. Topical compositions comprising these compounds are also provided. In particular, these topical compositions may further comprise photoactive compounds. Methods for stabilizing photoactive compounds are also provided. These methods comprise mixing the photoactive compounds with photostabilizing compounds.

Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.

An organic electroluminescence device includes a first electrode, a hole transport region on the first electrode, an emission layer on the hole transport region, an electron transport region on the emission layer, and a second electrode on the electron transport region. The hole transport region includes a monoamine compound represented by the following Formula 1: ##STR00001##

The present invention refers to a new process for the synthesis of (9,10)-pregn-4-ene-3,20-dione, commonly known as retroprogesterone, having the formula (1) shown below. ##STR00001##

The present disclosure relates to a novel compound represented by Chemical Formula 1 and an organic light emitting device using the same. The compound is used as a material of an organic material layer of the organic light emitting device.

##STR00001##

The present invention refers to a new process for the synthesis of (9,10)-pregn-4-ene-3,20-dione, commonly known as retroprogesterone, having the formula (1) shown below.

##STR00001##

There are described ROR modulators of the formula (I), ##STR00001##
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR activity, for example, autoimmune and/or inflammatory disorders.